Team:SZU China/Achievement
Achievement
Judging Criteria
In the past 9 months, we have gone through brainstorming, experimental design, biobrick combination, system verification, human practice and wiki making, ect. Through our hard work, our project has been greatly developed and we are fully prepared for the Giant Jamboree. We have submitted 12 biobricks and they are transiently transfected into different cell lines to verify the working efficiency of our system. What’s more, we performed our human practice with Cancer Mutual Aid Association, Shenzhen Sencond People’s Hospital and Moonbay Primary School. We also cooperate with Nankai and LZU-China. We believe we deserve Gold Medal since we have met all the requirements for it.
Judging Criteria
We have designed and constructed 12 parts, including 6 basic parts and 6 composite parts. Among all this parts, three of them are improved from previously existing Biobrick Part or Device. All of these parts were well documented on the part registry pages. They are listed as follows:
| Part Number | Nickname | Part Type |
|---|---|---|
| BBa_K1722000 | hUPII | Basic Part |
| BBa_K1722001 | shTERT | Basic Part(Improved) |
| BBa_K1722002 | hTERT | Basic Part |
| BBa_K1722004 | tRNA | Basic Part |
| BBa_K1722005 | Rluc | Basic Part(Improved) |
| BBa_K1722006 | SV40(En) | Basic Part(Improved) |
| BBa_K1722007 | hUPII+AckRS | Composite Part |
| BBa_K1722009 | hTERT+GFP | Composite Part |
| BBa_K1722010 | hTERT+tRNA | Composite Part |
| BBa_K1722011 | shTERT+tRNA | Composite Part |
| BBa_K1722011 | shTERT+tRNA | Composite Part |
| BBa_K1722013 | shTERT+tRNA | Composite Part |
hUPII(BBa_K1722000) is well documented in the registry and accepted. It is the highest quality basic part of our team and it deserves the Best Basic Part.
hUPII+AckRS(BBa_K1722007) is well documented in the registry and accepted. It is the highest quality composite part of our team and it deserves the Best Composite Part.
Human practice outside the lab
To further verifying the working efficiency of the unnatural amino acid orthogonal system, we replaced the amber mutated output gene in former plasmids to amber mutated GFP. The plasmid psiCHECKTM2-CMV-GFP was used as a positive control to monitor transfection and expression efficiency. The two plasmids and three plasmids system being constructed by GFP recombinant plasmids were transiently transfected into 5637 and T24, both of which are bladder cancer cell line.
Pictures of green fluorescent light produced by target cells were taken by fluorescent microscope. From these pictures (Fig. 3), we can see there is no expression of GFP being detected in no Ack groups while the light intensities are rather high in with Ack groups no matter in T24 or 5637 cell lines. These results indicate that the output gene is expressed only in cells which have Ack in the culture medium. These findings suggest that the constructed circuit based on AND GATE and UAA orthogonal system can be used to specifically identify bladder cancer cells, and may yield a new therapeutic approach for bladder cancer.
